Patient with a rectal cancer T₂N+ or T₃/T₄ of the mid or lower rectum treated by a neoadjuvant radiochemotherapy with 45 Gy ± 5 Gy local + 5FU

Inclusion and exclusion criteria verification

Inclusion & Randomization

**Groupe S7**
Delay: 7 weeks ± 5 days

**Groupe S11**
Delay: 11 weeks ± 5 days

Interval of 7 weeks

Interval of 11 weeks

Clinical evaluation of the response (*Rectal digital examination +/- (MRI)*)
Surgery: curative resection with total mesorectal excision

Histological exam:
- Complete pathological response (ypT0N0)
- Quality of the mesorectum
- Mortality rate (D90) and postoperative morbidity (D90)
- R0 resection rate, sphincter conservation rate

Follow-up M1 – M3
Stoma closure
Adjuvant chemotherapy
Late morbidity

Oncological Follow-up M6 – M60
Local and distant recurrences
Overall and disease-free survival

END OF THE TRIAL